Clinical trials: Stereotactic Body Radiation Therapy
Non-small Cell Lung Cancer Stage I
Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer
The primary objective of this phase 1 trial is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic gene therapy in combination with SBRT in medically inoperable…
- Trial name
- NSCLC (NCT03029871)
- Testing
- Ad5-yCD/mutTKSR39rep-ADP Adenovirus
- Where
- United States
- Sponsor
- Benjamin Movsas, M.D.
Lymphocyte Depletion
Lymphocyte Depletion and Change in Lymphocyte Functionality
Lymphocytes are a type of white blood cell (WBC) responsible for adaptive immunity. Thoracic tumors are adjacent to many blood/immune rich organs including the great vessels, heart, thoracic-spine, and lymph-node-stations.
- Trial name
- NCT04273893
- Testing
- SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Virginia
Cancer of Lung
4D CBCT and Intrafractional Imaging for the Determination of the Most Representative 4D Simulation Planning Technique for Lung SBRT Technique Patients
The researchers plan to investigate two ways of visualizing and planning to account for the respiratory motion which takes place while treating lung tumors with radiation therapy.
- Trial name
- NCT04717804
- Testing
- AIP CT, FB (Free-Breathing) CT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Palliative Radiotherapy
Palliative Lattice Stereotactic Body Radiotherapy (SBRT)
Standard palliative radiotherapy regimens may provide limited durability of response in large tumors. Thus, there is a clinical need for a new approach.
- Trial name
- NCT04133415
- Testing
- Lattice stereotactic body radiation therapy, Peripheral blood
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Melanoma
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445 given by intravenous infusion to subjects…
- Trial name
- NCT01973608
- Testing
- MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EMD Serono
Oligometastases of the Spine
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
In light of the increasing experience with magnetic resonance image-guided radiotherapy (MRgRT) and adaptive planning and advances in magnetic resonance (MR)-only planning, the investigators propose here to evaluate the…
- Trial name
- NCT03878485
- Testing
- MRIdian Linac System from ViewRay, Stereotactic MRI-guided Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity
- Trial name
- NCT04021043
- Testing
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases
Perfexion Brain Metastasis
Brain metastases occur in 20% to 40% of all patients with cancer , with an incidence 10 times higher than that of primary malignant brain tumors.
- Trial name
- HF-SRT (NCT00805103)
- Testing
- Hypofractionated stereotactic radiotherapy
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Gastrointestinal Neoplasms
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal…
- Trial name
- NCT06301828
- Testing
- Envafolimab Injection, Endostar
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology.
- Trial name
- SORT (NCT05183932)
- Where
- 8 sites in United States, Canada
- Volunteers
- 446 people
- Sponsor
- Washington University School of Medicine
Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
This randomized phase II trial studies how well transarterial chemoembolization (TACE) works compared with TACE plus radiation therapy in treating patients with end stage liver disease, liver tumors, or potential liver transplant…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer, Stage I Adult Primary Liver Cancer, Stage II Adult Primary Liver Cancer
- Trial name
- NCT02070419
- Testing
- transarterial chemoembolization, stereotactic radiosurgery
- Sponsor
- Case Comprehensive Cancer Center
Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis.
- Trial name
- NCT06374888
- Testing
- Neratinib maleate in combination with capecitabine
- Volunteers
- 28 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Advanced Head and Neck Cancer
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?
- Trial name
- NCT06641791
- Testing
- Standard Radiotherapy (SRT), Stereotactic Body Radiotherapy (SBRT)
- Where
- 10 sites in Canada
- Volunteers
- 196 people
- Sponsor
- Canadian Cancer Trials Group
Sarcoma, Metastatic Disease
Stereotactic Radiation Therapy for Pediatric Sarcomas
The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically…
- Conditions
- Sarcoma, Metastatic Disease, Bony Sites
- Trial name
- NCT01763970
- Testing
- SBRT
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC
Lung cancer is the leading cause of cancer death worldwide with a crude incidence of lung cancer in the European Union of 52/100.000 per year and a mortality of 47/100.000 per year.
- Trial name
- LungTech (NCT01795521)
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 6 sites in Belgium, Germany and 2 more
- Volunteers
- 39 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Metastases, Adult
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)
The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease.
- Trial name
- POSTPONE (NCT06029140)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Brest
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Spinal Metastases
Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost
Spinal metastases indicate for an incurable course of disease. Local tumor control after palliative radiotherapy of spinal metastases (10x3 Gy, 1x8Gy) is between 61 to 81%.
- Trial name
- SPIN-MET (NCT01849510)
- Testing
- hypofractionated 12x3 Gy + integrated boost 12x4 Gy, hypofractionated 10x3 Gy
- Where
- 3 sites in Germany
- Volunteers
- 155 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.